Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HR+/HER2- Breast Cancer
Interventions: DRUG: Tucidinostat|DRUG: nab-paclitaxel
Sponsor: Hunan Cancer Hospital